GREY:IMVIF - Post by User
Comment by
PoorOpinionon Nov 20, 2018 6:13pm
115 Views
Post# 29002079
RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:DPX-Survivac as Monotherapy For Recurring Ovarian Cancer
RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:DPX-Survivac as Monotherapy For Recurring Ovarian Canceralphaseeking001 wrote: Yikes... hoping it won't take that long to get breakthrough status...! Super excited about today's announcements BTW. They had already suspected that it was DPX-Survivac that was giving all the beneficial clinical effects and not Incyte's drug. This is much better for us.
If you want to get more positively excited about that drugs progress then Pharmacyclics seems to be the Small Cap behind that drug, its stock went from $5 to $120 over that time period and ended being sold for many billions. But dont say I said any of that, hate to fuel dreams!